Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
作者： Tammy F Chu , Maria A Rupnick , Risto Kerkela , Susan M Dallabrida , David Zurakowski
DOI: 10.1016/S0140-6736(07)61865-0
关键词: Heart failure 、 Cardiotoxicity 、 Sunitinib 、 Ejection fraction 、 Blood pressure 、 Stroke volume 、 Internal medicine 、 Medicine 、 Coronary artery disease 、 Myocardial infarction 、 Cardiology
摘要: … sunitinib's effects on left ventricular ejection fraction (LVEF) and blood pressure. We investigated potential mechanisms of sunitinib-… the mode of action of sunitinib in mouse models and …
elsevier.com
sci-hub.se 参考文章(31)
Mladosievicova B, Carter A, Urbanová D, Urban L, Maasova D, Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma. ,vol. 53, pp. 183- 190 ,(2006)
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
Katherine L. Osusky, Dennis E. Hallahan, Allie Fu, Fei Ye, Yu Shyr, Ling Geng, The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. ,vol. 7, pp. 225- 233 ,(2004) , 10.1007/S10456-004-3149-Y
Rakesh K Jain, Dan G Duda, Jeffrey W Clark, Jay S Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature Reviews Clinical Oncology. ,vol. 3, pp. 24- 40 ,(2006) , 10.1038/NCPONC0403
Thomas Force, Daniela S. Krause, Richard A. Van Etten, Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer. ,vol. 7, pp. 332- 344 ,(2007) , 10.1038/NRC2106
Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand, Thomas Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine. ,vol. 12, pp. 908- 916 ,(2006) , 10.1038/NM1446
C BAINES, J MOLKENTIN, STRESS signaling pathways that modulate cardiac myocyte apoptosis. Journal of Molecular and Cellular Cardiology. ,vol. 38, pp. 47- 62 ,(2005) , 10.1016/J.YJMCC.2004.11.004
Miles A Fabian, William H Biggs, Daniel K Treiber, Corey E Atteridge, Mihai D Azimioara, Michael G Benedetti, Todd A Carter, Pietro Ciceri, Philip T Edeen, Mark Floyd, Julia M Ford, Margaret Galvin, Jay L Gerlach, Robert M Grotzfeld, Sanna Herrgard, Darren E Insko, Michael A Insko, Andiliy G Lai, Jean-Michel Lélias, Shamal A Mehta, Zdravko V Milanov, Anne Marie Velasco, Lisa M Wodicka, Hitesh K Patel, Patrick P Zarrinkar, David J Lockhart, A small molecule–kinase interaction map for clinical kinase inhibitors Nature Biotechnology. ,vol. 23, pp. 329- 336 ,(2005) , 10.1038/NBT1068
Richard J Pietras, Mark D Pegram, Richard S Finn, Daniel A Maneval, Dennis J Slamon, Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. ,vol. 17, pp. 2235- 2249 ,(1998) , 10.1038/SJ.ONC.1202132
Dong Wook Kim, Young Suk Jo, Hye Sook Jung, Hyo Kyun Chung, Jung Hun Song, Ki Cheol Park, Su Hyeon Park, Jung Hwan Hwang, So Young Rha, Gi Ryang Kweon, Su-Jae Lee, Ki-Won Jo, Minho Shong, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. The Journal of Clinical Endocrinology and Metabolism. ,vol. 91, pp. 4070- 4076 ,(2006) , 10.1210/JC.2005-2845